In8bio (INAB) closed at $0.82 on November 17, 2026, up 0.5% from the previous close, on volume of 106,896 shares (30-day average 202,828).
Data as of November 17, 2026.
Analysts Are Bullish on Top Healthcare Stocks: PepGen Inc. (PEPG), IN8bio (INAB)
TipRanks (Mon, 16-Nov 12:00 PM ET)
Globe Newswire (Mon, 16-Nov 8:00 AM ET)
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 6-Nov 4:01 PM ET)
IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Globe Newswire (Thu, 5-Nov 4:01 PM ET)
IN8bio to Present at Sidoti Small-Cap Virtual Conference
Globe Newswire (Tue, 22-Sep 4:00 PM ET)
IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference
Globe Newswire (Thu, 10-Sep 8:00 AM ET)
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
Globe Newswire (Wed, 9-Sep 8:00 AM ET)
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
In8bio trades on the NASDAQ stock market under the symbol INAB.
As of November 18, 2026, INAB stock price declined to $0.78 with 12,544 million shares trading.
INAB has a beta of 1.69, meaning it tends to be more sensitive to market movements. INAB has a correlation of 0.04 to the broad based SPY ETF.
INAB has a market cap of $8.43 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, INAB traded as high as $74.40 and as low as $.72.
The top ETF exchange traded funds that INAB belongs to (by Net Assets): VXF, VTI.
INAB has underperformed the market in the last year with a price return of -50.9% while the SPY ETF gained +10.4%. INAB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -29.7% and -17.9%, respectively, while the SPY returned -5.6% and -3.6%, respectively.
INAB support price is $.76 and resistance is $.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INAB shares will trade within this expected range on the day.